CoChat

An alphaherpesvirus exploits antimicrobial β-Defensins to initiate respiratory tract infection.

Open access

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems. We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis. In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells. In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3. Infected cells synthesized eBD2 and -3, promoting further host cell invasion by EHV1. Finally, eBD1, -2, and -3 recruited leukocytes, which are well-known EHV1 dissemination and latency vessels. The exploitation of host innate defenses by herpesviruses during the early phase of host colonization indicates that highly specialized strategies have developed during host-pathogen coevolution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jvi.01676-19

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG 1 Validation of synthetic peptides and BD antibodies. (A) (Left) Western blot analysis of synthetic eBD1, -2, and -3 using the anti-human BD antibodies (α-hBD Ab) or isotype control antibodies (Co Ab). (Right) Western blotting to determine the cross-reactivity of the sera between eBDs and hBDs (top) and Coomassie blue staining of a Western blot membrane of eBD1 and hBD1 (bottom). The sizes (in kilodaltons) of the molecular weight markers are shown. (B) Work flow used to validate eBD oxidation via LC-MS analysis. Commercially synthesized eBD1, -2, and -3 (shown in blue) were folded through air oxidation (eBD2 and -3) or DMSO oxidation (eBD1). Disulfide bonds between cysteine molecules are shown in yellow. Next, bottom-up analysis was performed in triplicate to confirm oxidation of the eBDs and quantify the relative abundance of disulfide bridges in the oxidized versus reduced forms. Free cysteine molecules (yellow) in the reduced and oxidizede eBD1, -2, and -3 mixtures were alkylated by adding methyl methanethiosulfonate (MMTS; red dots) prior to overnight digestion in trypsin. The peptides were then identified through LC-ESI-MS. (C) (Top) Amino acid sequences of eBD1, -2, and -3. Amino acids indicated in gray were not covered in the MS bottom-up analysis. (Bottom) Relative abundance of disulfide bridge formation in the reduced and oxidized eBD1, -2, and -3 mixture. (D) Detection of the undigested oxidized form of eBD2. The small region of interest of the aggregate run from the eBD2 analysis is shown in three dimensions, comprising m/z, retention time (RT), and intensity as the dimensions. (Top) The signal of 1,082.767 (4+) is delineated in pink at a retention time of 39.0 min in both the reduced and the oxidized forms. (Bottom) Two-dimensional representations (retention time versus m/z) of extended regions of the LC-MS are shown. (Left) The 4+ form is highlighted in pink coeluting with its 5+ form (866.416), and the 5+ minus alanine (852.207) form is highlighted in brown. (Right) Complete overview of the aggregate LC-MS run (i.e., joint representation of the six runs on eBD2), with the region of interest depicted by the zoom box.
FIG 1 Validation of synthetic peptides and BD antibodies. (A) (Left) Western blot analysis of synthetic eBD1, -2, and -3 using the anti-human BD antibodies (α-hBD Ab) or isotype control antibodies (Co Ab). (Right) Western blotting to determine the cross-reactivity of the sera between eBDs and hBDs (top) and Coomassie blue staining of a Western blot membrane of eBD1 and hBD1 (bottom). The sizes (in kilodaltons) of the molecular weight markers are shown. (B) Work flow used to validate eBD oxidation via LC-MS analysis. Commercially synthesized eBD1, -2, and -3 (shown in blue) were folded through air oxidation (eBD2 and -3) or DMSO oxidation (eBD1). Disulfide bonds between cysteine molecules are shown in yellow. Next, bottom-up analysis was performed in triplicate to confirm oxidation of the eBDs and quantify the relative abundance of disulfide bridges in the oxidized versus reduced forms. Free cysteine molecules (yellow) in the reduced and oxidizede eBD1, -2, and -3 mixtures were alkylated by adding methyl methanethiosulfonate (MMTS; red dots) prior to overnight digestion in trypsin. The peptides were then identified through LC-ESI-MS. (C) (Top) Amino acid sequences of eBD1, -2, and -3. Amino acids indicated in gray were not covered in the MS bottom-up analysis. (Bottom) Relative abundance of disulfide bridge formation in the reduced and oxidized eBD1, -2, and -3 mixture. (D) Detection of the undigested oxidized form of eBD2. The small region of interest of the aggregate run from the eBD2 analysis is shown in three dimensions, comprising m/z, retention time (RT), and intensity as the dimensions. (Top) The signal of 1,082.767 (4+) is delineated in pink at a retention time of 39.0 min in both the reduced and the oxidized forms. (Bottom) Two-dimensional representations (retention time versus m/z) of extended regions of the LC-MS are shown. (Left) The 4+ form is highlighted in pink coeluting with its 5+ form (866.416), and the 5+ minus alanine (852.207) form is highlighted in brown. (Right) Complete overview of the aggregate LC-MS run (i.e., joint representation of the six runs on eBD2), with the region of interest depicted by the zoom box.CC BY · PubMed Central
FIG 2 Distribution of eBD1, -2, and -3 across the equine respiratory tract. (A) mRNA expression of eBD1, -2, and -3 in the equine nasal septum, trachea, and lungs. (B) Representative confocal images of eBD1, -2, and -3 protein expression (green) in the equine nasal septum, trachea, and lungs. Cell nuclei were counterstained with Hoechst (blue). Bars, 50 μm.
FIG 2 Distribution of eBD1, -2, and -3 across the equine respiratory tract. (A) mRNA expression of eBD1, -2, and -3 in the equine nasal septum, trachea, and lungs. (B) Representative confocal images of eBD1, -2, and -3 protein expression (green) in the equine nasal septum, trachea, and lungs. Cell nuclei were counterstained with Hoechst (blue). Bars, 50 μm.CC BY · PubMed Central
FIG 3 Antiviral activity of eBD1, -2, and -3 during a virus plaque assay on continuous cell lines. The impact of eBD1 (left), eBD2 (middle), and eBD3 (right) was tested on different steps in the infection of continuous cell lines (RK13 cells for EHV1 and EVA or MDCK cells for EIV) with EHV1 (MOI, 0.001), EIV (MOI, 0.001), and EVA (MOI, 0.001). Experiments were performed in triplicate. Significant differences are indicated by asterisks: **, P < 0.01; ***, P < 0.001. (A) Virus particles were pretreated with 0 to 100 μg/ml eBD1, -2, and -3 prior to inoculation for 2 h at 4°C. Heparin (Hep; 100 U/ml) was used as a positive internal control for blocking subsequent EHV1 binding. (B) Cells were pretreated with 0 to 100 μg/ml eBD1, -2, and -3 prior to virus inoculation for 2 h at 4°C. (C) eBD1, -2, and -3 (0 to 100 μg/ml) were added during the virus entry step for 1 h at 37°C. (D) Following citrate treatment (pH 3), 0 to 100 μg/ml eBD1, -2, and -3 was added to the inoculated cells during the virus postpenetration step for 48 h. Ganciclovir (Gan; 10 μg/ml) was used as a positive internal control to block EHV1 replication.
FIG 3 Antiviral activity of eBD1, -2, and -3 during a virus plaque assay on continuous cell lines. The impact of eBD1 (left), eBD2 (middle), and eBD3 (right) was tested on different steps in the infection of continuous cell lines (RK13 cells for EHV1 and EVA or MDCK cells for EIV) with EHV1 (MOI, 0.001), EIV (MOI, 0.001), and EVA (MOI, 0.001). Experiments were performed in triplicate. Significant differences are indicated by asterisks: **, P < 0.01; ***, P < 0.001. (A) Virus particles were pretreated with 0 to 100 μg/ml eBD1, -2, and -3 prior to inoculation for 2 h at 4°C. Heparin (Hep; 100 U/ml) was used as a positive internal control for blocking subsequent EHV1 binding. (B) Cells were pretreated with 0 to 100 μg/ml eBD1, -2, and -3 prior to virus inoculation for 2 h at 4°C. (C) eBD1, -2, and -3 (0 to 100 μg/ml) were added during the virus entry step for 1 h at 37°C. (D) Following citrate treatment (pH 3), 0 to 100 μg/ml eBD1, -2, and -3 was added to the inoculated cells during the virus postpenetration step for 48 h. Ganciclovir (Gan; 10 μg/ml) was used as a positive internal control to block EHV1 replication.CC BY · PubMed Central
FIG 4 Effect of eBD1, -2, and -3 on EHV1 spread in RK13 cells. eBD1 (top left), eBD2 (top middle), or eBD3 (top right) was added at 0 to 100 μg/ml to the virus in the virus pretreatment step (A) or to EHV1-inoculated RK13 cells during the virus postpenetration step (B). Data from three independent experiments are represented as means + SD (top). Significant differences are indicated by asterisks: *, P ≤ 0.05; **, P < 0.01; ***, P < 0.001. Heparin (Hep; 100 U/ml) was used as a positive internal control during virus pretreatment for blocking subsequent EHV1 binding. Ganciclovir (Gan; 10 g/ml) was used as a positive internal control to block EHV1 replication. Representative images of EHV1 plaques in crystal violet-stained RK13 cell monolayers in the bottom panels of A and B. Bars, 200 μm.
FIG 4 Effect of eBD1, -2, and -3 on EHV1 spread in RK13 cells. eBD1 (top left), eBD2 (top middle), or eBD3 (top right) was added at 0 to 100 μg/ml to the virus in the virus pretreatment step (A) or to EHV1-inoculated RK13 cells during the virus postpenetration step (B). Data from three independent experiments are represented as means + SD (top). Significant differences are indicated by asterisks: *, P ≤ 0.05; **, P < 0.01; ***, P < 0.001. Heparin (Hep; 100 U/ml) was used as a positive internal control during virus pretreatment for blocking subsequent EHV1 binding. Ganciclovir (Gan; 10 g/ml) was used as a positive internal control to block EHV1 replication. Representative images of EHV1 plaques in crystal violet-stained RK13 cell monolayers in the bottom panels of A and B. Bars, 200 μm.CC BY · PubMed Central
FIG 5 Antiviral activity of eBD1, -2, and -3 during a virus plaque assay on primary EREC. (A) Virus particles were pretreated with 0 or 100 μg/ml eBD1, -2, and -3 prior to inoculation for 2 h at 4°C. (B) Cells were pretreated with 0 or 100 μg/ml eBD1, -2, and -3 prior to virus inoculation for 2 h at 4°C. (C) eBD1, -2, and -3 (0 or 100 μg/ml) were added during the virus entry step for 1 h at 37°C. (D) Following citrate treatment (pH 3), 0 or 100 μg/ml eBD1, -2, and -3 was added to the inoculated cells during the virus postpenetration step for 48 h. Ganciclovir (Gan; 10 μg/ml) was used as a positive internal control to block EHV1 replication. Experiments were performed in triplicate on primary EREC from three different horses. Data are represented as means + SD, and significant differences are indicated by asterisks: *, P ≤ 005; **, P < 0.01; ***, P < 0.001. Representative confocal images of EHV1-positive plaques or EIV-positive individual cells (green) are shown on the right for each step. Cell nuclei were counterstained with Hoechst (blue). Bars, 75 μm.
FIG 5 Antiviral activity of eBD1, -2, and -3 during a virus plaque assay on primary EREC. (A) Virus particles were pretreated with 0 or 100 μg/ml eBD1, -2, and -3 prior to inoculation for 2 h at 4°C. (B) Cells were pretreated with 0 or 100 μg/ml eBD1, -2, and -3 prior to virus inoculation for 2 h at 4°C. (C) eBD1, -2, and -3 (0 or 100 μg/ml) were added during the virus entry step for 1 h at 37°C. (D) Following citrate treatment (pH 3), 0 or 100 μg/ml eBD1, -2, and -3 was added to the inoculated cells during the virus postpenetration step for 48 h. Ganciclovir (Gan; 10 μg/ml) was used as a positive internal control to block EHV1 replication. Experiments were performed in triplicate on primary EREC from three different horses. Data are represented as means + SD, and significant differences are indicated by asterisks: *, P ≤ 005; **, P < 0.01; ***, P < 0.001. Representative confocal images of EHV1-positive plaques or EIV-positive individual cells (green) are shown on the right for each step. Cell nuclei were counterstained with Hoechst (blue). Bars, 75 μm.CC BY · PubMed Central
FIG 6 Role of glycoprotein M and virion surface glycans in EHV1 resistance against eBD2 and the eBD2-induced increase in EHV1 infection, respectively. (A) The EHV1 03P37 strain, the parental RacL11 strain, the RacL11 strain lacking glycoprotein 2 (gp2), and the RacL11 strain lacking glycoprotein M (gM) were pretreated with 0 or 100 μg/ml eBD2 prior to inoculation of RK13 cell monolayers. (B) The EHV1 03P37 strain was pretreated or not pretreated with PNGase F (25,000 U/ml) overnight prior to treatment with eBD2 and inoculation of RK13 cell monolayers. Experiments were performed in triplicate, and significant differences are indicated by asterisks: *, P ≤ 0.05; ***, P < 0.001.
FIG 6 Role of glycoprotein M and virion surface glycans in EHV1 resistance against eBD2 and the eBD2-induced increase in EHV1 infection, respectively. (A) The EHV1 03P37 strain, the parental RacL11 strain, the RacL11 strain lacking glycoprotein 2 (gp2), and the RacL11 strain lacking glycoprotein M (gM) were pretreated with 0 or 100 μg/ml eBD2 prior to inoculation of RK13 cell monolayers. (B) The EHV1 03P37 strain was pretreated or not pretreated with PNGase F (25,000 U/ml) overnight prior to treatment with eBD2 and inoculation of RK13 cell monolayers. Experiments were performed in triplicate, and significant differences are indicated by asterisks: *, P ≤ 0.05; ***, P < 0.001.CC BY · PubMed Central
FIG 7 Role of eBD1, -2, and -3 in the attachment of EHV1 to cells. (A) The binding of eBD1, -2, and -3 (0 or 100 μg/ml)-pretreated and DiO-labeled EHV1 particles to RK13 cells. (B) The attachment of untreated and DiO-labeled EHV1 particles to eBD1, -2, and -3 (0 or 100 μg/ml)-pretreated EREC. (Top left) The percentage of cells with bound virus. (Top right) The total number of particles counted per EHV1-positive cell. Three independent experiments were performed with RK13 cells, and EREC from three different horses were used. Data are represented as means + SD, and significant differences are indicated by asterisks: *, P ≤ 0.05; ***, P < 0.001. (Bottom) Representative confocal z-stack images of eBD1, -2, and -3-pretreated and DiO-labeled EHV1 particles (green) attached to RK13 cells (A) or untreated and DiO-labeled EHV1 particles (green) bound to eBD1, -2, and -3-pretreated EREC (B). Note the virus aggregates (arrows) bound to the RK13 cells upon virus pretreatment with eBD2 and -3. Magnified (×4) images are shown in the lower left corner of each picture. Cell nuclei were counterstained with Hoechst (blue). Bars, 10 μm.
FIG 7 Role of eBD1, -2, and -3 in the attachment of EHV1 to cells. (A) The binding of eBD1, -2, and -3 (0 or 100 μg/ml)-pretreated and DiO-labeled EHV1 particles to RK13 cells. (B) The attachment of untreated and DiO-labeled EHV1 particles to eBD1, -2, and -3 (0 or 100 μg/ml)-pretreated EREC. (Top left) The percentage of cells with bound virus. (Top right) The total number of particles counted per EHV1-positive cell. Three independent experiments were performed with RK13 cells, and EREC from three different horses were used. Data are represented as means + SD, and significant differences are indicated by asterisks: *, P ≤ 0.05; ***, P < 0.001. (Bottom) Representative confocal z-stack images of eBD1, -2, and -3-pretreated and DiO-labeled EHV1 particles (green) attached to RK13 cells (A) or untreated and DiO-labeled EHV1 particles (green) bound to eBD1, -2, and -3-pretreated EREC (B). Note the virus aggregates (arrows) bound to the RK13 cells upon virus pretreatment with eBD2 and -3. Magnified (×4) images are shown in the lower left corner of each picture. Cell nuclei were counterstained with Hoechst (blue). Bars, 10 μm.CC BY · PubMed Central
FIG 8 Viral infections elicit eBD2 and -3 protein expression in EREC. Cells were either mock inoculated or inoculated with EHV1 (MOI, 0.2) or EIV (MOI, 2) for 18 h. (Top left) The mean percentage of the eBD1 (left), eBD2 (middle), or eBD3 (right) fluorescent signal was calculated on 5 complete z-stack confocal images using ImageJ software. The mean fluorescent signal of the mock-inoculated cells (black bars) was compared to that of EHV1- or EIV-inoculated cells, with the last two groups containing infected as well as noninfected areas. Experiments were performed in triplicate on primary EREC from three different horses. Data are represented as means + SD, and significant differences are indicated by asterisks: ***, P < 0.001. (Top right and bottom) Representative confocal z-stack images of eBD1, -2, and -3 protein expression in mock-, EHV1-, or EIV-inoculated EREC, with the last two groups containing infected as well as noninfected areas. eBD1, -2, and -3 were visualized in green, while EHV1 late proteins and EIV nucleoprotein were simultaneously stained in red to distinguish infected from noninfected areas. Cell nuclei were counterstained with Hoechst (blue). Bars, 10 μm.
FIG 8 Viral infections elicit eBD2 and -3 protein expression in EREC. Cells were either mock inoculated or inoculated with EHV1 (MOI, 0.2) or EIV (MOI, 2) for 18 h. (Top left) The mean percentage of the eBD1 (left), eBD2 (middle), or eBD3 (right) fluorescent signal was calculated on 5 complete z-stack confocal images using ImageJ software. The mean fluorescent signal of the mock-inoculated cells (black bars) was compared to that of EHV1- or EIV-inoculated cells, with the last two groups containing infected as well as noninfected areas. Experiments were performed in triplicate on primary EREC from three different horses. Data are represented as means + SD, and significant differences are indicated by asterisks: ***, P < 0.001. (Top right and bottom) Representative confocal z-stack images of eBD1, -2, and -3 protein expression in mock-, EHV1-, or EIV-inoculated EREC, with the last two groups containing infected as well as noninfected areas. eBD1, -2, and -3 were visualized in green, while EHV1 late proteins and EIV nucleoprotein were simultaneously stained in red to distinguish infected from noninfected areas. Cell nuclei were counterstained with Hoechst (blue). Bars, 10 μm.CC BY · PubMed Central
FIG 9 Chemotactic activity of eBD1, -2, and -3 on equine blood leukocytes. Migration of neutrophils (A), CD172a+ monocytes (B), and CD3+ T lymphocytes (C) induced by 0 to 10 μg/ml eBD1 (left), eBD2 (middle), or eBD3 (right). Fetal calf serum (FCS) was used as an internal positive control. Experiments were performed in triplicate on blood leukocyte subpopulations from three different healthy horse donors. Cell migration values are reported as relative fluorescence units (RFU) and represented as means + SD. Significant differences are indicated by asterisks: *, P ≤ 0.05; **, P < 0.01; ***, P < 0.001.
FIG 9 Chemotactic activity of eBD1, -2, and -3 on equine blood leukocytes. Migration of neutrophils (A), CD172a+ monocytes (B), and CD3+ T lymphocytes (C) induced by 0 to 10 μg/ml eBD1 (left), eBD2 (middle), or eBD3 (right). Fetal calf serum (FCS) was used as an internal positive control. Experiments were performed in triplicate on blood leukocyte subpopulations from three different healthy horse donors. Cell migration values are reported as relative fluorescence units (RFU) and represented as means + SD. Significant differences are indicated by asterisks: *, P ≤ 0.05; **, P < 0.01; ***, P < 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Cited by

See all 13

Metadata

Authors
Van Cleemput, J., Poelaert, K. C. K., Laval, K., Vanderheijden, N., Dhaenens, M., Daled, S., Boyen, F., Pasmans, F., & Nauwynck, H. J.
Affiliations
  • Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
  • Fox Chase Cancer Center (US)
  • Princeton University (US)
  • Ghent University (BE)
Corresponding author
Nauwynck, Hans J.
Venue
Journal of Virology
Published
2020-03-31
Volume
94
Issue
8
ISSN
  • 0022-538X (ISSN-L)
  • 1098-5514
OpenAlex
W3003895548
Cited by
13
References
71
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 2
FWCI
1.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Virology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (publishedVersion, other-oa)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
Funders
  • Fonds Wetenschappelijk Onderzoek (11Y5415N)
  • Agentschap voor Innovatie door Wetenschap en Technologie (141627)
  • Bijzonder Onderzoeksfonds (01G01317)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Keywords
alphaherpesvirus, equine herpesvirus 1, host innate immunity, respiratory infections, glycoprotein M, host cell invasion, airway epithelial cells, leukocyte recruitment, viral latency, host-pathogen coevolution, equine respiratory disease
MeSH terms
Animals, Anti-Infective Agents, Cell Line, Epithelial Cells, Herpesvirus 1, Equid, Herpesviridae Infections, Horse Diseases, Horses, Rabbits, Respiratory Tract Infections, Viral Envelope Proteins, Alphaherpesvirinae, beta-Defensins, Host-Pathogen Interactions, Immune Evasion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An alphaherpesvirus exploits antimicrobial β-Defensins to initiate respiratory tract infection. https://app.cochat.ai/papers/10.1128/jvi.01676-19
The paper
Van Cleemput, J., Poelaert, K. C. K., Laval, K., Vanderheijden, N., Dhaenens, M., Daled, S., Boyen, F., Pasmans, F., & Nauwynck, H. J. (2020). An alphaherpesvirus exploits antimicrobial β-Defensins to initiate respiratory tract infection. Journal of Virology. https://doi.org/10.1128/jvi.01676-19

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.